<DOC>
	<DOC>NCT00336284</DOC>
	<brief_summary>This study is a multi-center, prospective and randomized trial. The primary objective of this study is to demonstrate that the use of the BIOTRONIK Home Monitoring system (HM) can safely reduce the number of regularly scheduled office follow-up visits, compared to the conventional method of implantable cardioverter defibrillator (ICD) follow-up.</brief_summary>
	<brief_title>TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up</brief_title>
	<detailed_description />
	<criteria>Implanted within the last 45 days or being considered for implant with a BIOTRONIK ICD with Home Monitoring (HM)/Intracardiac Electrogram (IEGM)Online technology, or legally marketed future generation device with HM/IEGM Online. Able to utilize the HM system throughout the study Ability to give informed consent Geographically stable and able to return for regular followups for fifteen (15) months At least 18 years old Patients who do not fulfill all inclusion criteria Pacemaker dependent Currently enrolled in any other cardiac clinical investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Telemonitoring</keyword>
	<keyword>ICD</keyword>
	<keyword>Reduction of office follow-ups</keyword>
</DOC>